Expertise in
1
conditions

Yvette Drew

Framlington Place, 
Newcastle Upon Tyne, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Framlington Place, 
Newcastle Upon Tyne, ENG, GB 
OverviewLocationsClinical Research

Overview

Yvette Drew practices in Newcastle Upon Tyne, United Kingdom. Ms. Drew is highly rated in 1 condition, according to our data. Her top areas of expertise are Ovarian Cancer, Cervical Cancer, Ataxia-Telangiectasia, and Telangiectasia.

Her clinical research consists of co-authoring 46 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Framlington Place, Newcastle Upon Tyne, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: March 03, 2025
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drug: Enapotamab vedotin 
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

46 Total Publications

Clearing the Path for Immunologic Targeting of Gynecologic Clear Cell Carcinomas.
Clearing the Path for Immunologic Targeting of Gynecologic Clear Cell Carcinomas.
Journal: JAMA oncology
Published: July 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Drew's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile